NCT00862823View on ClinicalTrials.gov

The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

May 31, 2010

Conditions
Healthy
Interventions
DRUG

tenofovir, emtricitabine and efavirenz fixed dose tablet

Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz

DRUG

tenofovir, emtricitabine and efavirenz tablet added to solution

Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Alabama at Birmingham

OTHER